In this work, we have constructed a novel mechanistic quantitative systems pharmacology model describing the underlying pathophysiological processes of HER2+ BC, from ligand-receptor binding to downstream signaling and finally to tumor growth, while incorporating the distinct modalities and mechanisms of various state-of-the-art therapeutics. This evidence concerns the gene ERBB2 and breast cancer.